Novartis AG $NVS Shares Sold by Family Manage LLC

Family Manage LLC lowered its holdings in Novartis AG (NYSE:NVS) by 92.7% during the first quarter, HoldingsChannel.com reports. The fund owned 1,493 shares of the company’s stock after selling 18,845 shares during the period. Family Manage LLC’s holdings in Novartis were worth $228,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Arlington Trust Co LLC bought a new stake in shares of Novartis in the 4th quarter worth approximately $25,000. Archer Investment Corp boosted its position in Novartis by 93.0% during the 1st quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after purchasing an additional 80 shares during the period. CrossGen Wealth LLC bought a new position in Novartis during the 4th quarter worth $28,000. Bank of Jackson Hole Trust grew its stake in Novartis by 425.0% during the 4th quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock worth $32,000 after buying an additional 187 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC acquired a new stake in Novartis in the third quarter worth $33,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Citigroup reiterated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings lowered shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $141.20.

Novartis Stock Performance

NVS opened at $156.13 on Tuesday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The business’s 50 day moving average is $152.09 and its 200-day moving average is $152.33. The stock has a market cap of $297.91 billion, a PE ratio of 23.55, a price-to-earnings-growth ratio of 2.68 and a beta of 0.45. Novartis AG has a twelve month low of $112.34 and a twelve month high of $170.46.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The business had revenue of $14.95 billion during the quarter. On average, analysts predict that Novartis AG will post 8.77 earnings per share for the current year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.